SC
CNTX icon

Shay Capital’s Context Therapeutics CNTX Stock Holding History

Shay Capital’s Portfolio CNTX Stock Details CNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-189,853
Closed -$116K – 346
2025
Q1 		$116K Buy
189,853
+139,853
+280% +$122K 0.02% 266
2024
Q4 		$52.5K Buy
+50,000
New +$86.5K 0.01% 290

Other funds holding CNTX

MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.51% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Shay Capital's CNTX Position: Q2 2025 in Review

Shay Capital sold out of Context Therapeutics (CNTX) in Q2 2025, closing a stake of 189,853 shares — an estimated $116K sold.

Shay Capital first reported a position in CNTX in Q4 2024 and held it in 2 quarters. The position peaked at $116K in Q1 2025. 39 funds tracked by Wall St. Rank hold CNTX as of Q2 2025.

  • Shay Capital reported no remaining Context Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Shay Capital sold 189,853 Context Therapeutics shares in Q2 2025, an estimated $116K.
  • Shay Capital first reported a position in Context Therapeutics in Q4 2024 and held it in 2 quarters.
  • Shay Capital's Context Therapeutics position peaked at $116K in Q1 2025.
  • 39 funds tracked by Wall St. Rank held Context Therapeutics as of Q2 2025.

Based on Shay Capital's 13F filing for Q2 2025, filed 14 Aug 2025.